Head to head
BPC-157 against VIP
Both are compounded and sold for inflammation, and their evidence is differently thin. VIP is a natural signalling peptide used intranasally for chronic inflammatory conditions; BPC-157's human record is two rectal enema studies and three uncontrolled clinic reports.
Column A
BPC-157Body Protection Compound 157
A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.
Column B
VIPVasoactive Intestinal Peptide
A signaling peptide with broad roles in immunity, inflammation, and blood flow, studied intranasally for chronic inflammatory conditions.
Side by side, on the facts we can check
| Attribute | BPC-157 | VIP |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action | Not broadly FDA-approved; used off-label / compounded |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | ~1-2 minutes (native) |
| Molecular weight | 1,419.5 Da | 3,326.8 Da |
| Mechanism | In animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days. | Activates VPAC receptors to modulate immune and inflammatory signaling, relax smooth muscle, and dilate blood vessels. |
| Human studies cited | 5 | 2 |
| Legal status, US | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between BPC-157 and VIP?
BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. VIP: A signaling peptide with broad roles in immunity, inflammation, and blood flow, studied intranasally for chronic inflammatory conditions.
Which has stronger research evidence, BPC-157 or VIP?
This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 2 of 3 for VIP. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are BPC-157 and VIP FDA-approved?
BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. VIP: Not broadly FDA-approved; used off-label / compounded.
Related posts
Blog articles that cover BPC-157 or VIP, newest first.
- Healing & Recovery / Sep 8, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 8, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.